{"protocolSection":{"identificationModule":{"nctId":"NCT03631784","orgStudyIdInfo":{"id":"3475-799"},"secondaryIdInfos":[{"id":"MK-3475-799","type":"OTHER","domain":"MSD Protocol Number"},{"id":"2018-000714-37","type":"EUDRACT_NUMBER"}],"organization":{"fullName":"Merck Sharp & Dohme LLC","class":"INDUSTRY"},"briefTitle":"A Trial of Pembrolizumab in Combination With Chemotherapy and Radiotherapy in Stage III NSCLC (KEYNOTE-799, MK-3475-799)","officialTitle":"A Phase 2 Trial of Pembrolizumab (MK-3475) in Combination With Platinum Doublet Chemotherapy and Radiotherapy for Participants With Unresectable, Locally Advanced Stage III Non-Small Cell Lung Cancer (NSCLC) (KEYNOTE-799)","acronym":"KEYNOTE-799"},"statusModule":{"statusVerifiedDate":"2025-03","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2018-10-19","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2021-10-18","type":"ACTUAL"},"completionDateStruct":{"date":"2024-03-19","type":"ACTUAL"},"studyFirstSubmitDate":"2018-08-13","studyFirstSubmitQcDate":"2018-08-13","studyFirstPostDateStruct":{"date":"2018-08-15","type":"ACTUAL"},"resultsFirstSubmitDate":"2022-10-06","resultsFirstSubmitQcDate":"2022-10-06","resultsFirstPostDateStruct":{"date":"2022-11-02","type":"ACTUAL"},"lastUpdateSubmitDate":"2025-03-06","lastUpdatePostDateStruct":{"date":"2025-03-25","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Merck Sharp & Dohme LLC","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":true,"isFdaRegulatedDrug":true,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"This is a trial in adult participants with unresectable, locally advanced, Stage III non-small cell lung cancer (NSCLC) treated with pembrolizumab in combination with platinum doublet chemotherapy and standard thoracic radiotherapy followed by pembrolizumab monotherapy. The primary hypothesis of the trial is that within each platinum doublet chemotherapy cohort, the percentage of participants who develop Grade 3 or higher pneumonitis is ≤10% and estimation of objective response rate (ORR) by blinded independent central review (BICR)."},"conditionsModule":{"conditions":["Non-small Cell Lung Cancer"],"keywords":["Programmed Cell Death-1 (PD1, PD-1)","Programmed Cell Death 1 Ligand 1 (PDL1, PD-L1)","Programmed Cell Death 1 Ligand 2 (PDL2, PD-L2)"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE2"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"DOUBLE","whoMasked":["PARTICIPANT","INVESTIGATOR"]}},"enrollmentInfo":{"count":216,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Cohort A","type":"EXPERIMENTAL","description":"Participants received 1 cycle of carboplatin area under the curve (AUC) 6 mg/mL/min with paclitaxel 200 mg/m\\^2 and pembrolizumab 200 mg on Day 1. Approximately 3 weeks later, participants received carboplatin AUC 2 mg/mL/min with paclitaxel 45 mg/ m\\^2 administered weekly for 6 weeks along with 2 cycles of pembrolizumab 200 mg administered every 3 weeks (Q3W) in conjunction with standard thoracic radiotherapy (TRT) (60 Gray \\[Gy\\] in 2 Gy fractions administered 5 days per week for 6 weeks). Participants then received 14 additional cycles of pembrolizumab 200 mg administered Q3W. 1 cycle=21 days.","interventionNames":["Drug: Pembrolizumab 200 mg","Drug: Paclitaxel 45 mg/m^2","Drug: Carboplatin AUC6","Radiation: Thoracic Radiation Therapy (TRT)","Drug: Paclitaxel 200 mg/m^2","Drug: Carboplatin AUC2"]},{"label":"Cohort B","type":"EXPERIMENTAL","description":"Participants received 3 cycles of cisplatin 75 mg/m\\^2 with pemetrexed 500 mg/m\\^2 and pembrolizumab 200 mg on Day 1 of each cycle. Treatment was given in conjunction with standard TRT (60 Gy in 2 Gy fractions administered 5 days per week for 6 weeks) in cycles 2 and 3. Participants then received 14 additional cycles of pembrolizumab 200 mg administered Q3W. 1 cycle=21 days.","interventionNames":["Drug: Pembrolizumab 200 mg","Drug: Cisplatin 75 mg/m^2","Drug: Pemetrexed 500 mg/m^2","Radiation: Thoracic Radiation Therapy (TRT)"]}],"interventions":[{"type":"DRUG","name":"Pembrolizumab 200 mg","description":"Pembrolizumab 200 mg intravenous (IV) infusion on Days 1 of each 3-week cycle for up to 17 cycles","armGroupLabels":["Cohort A","Cohort B"],"otherNames":["MK-3475"]},{"type":"DRUG","name":"Paclitaxel 45 mg/m^2","description":"Paclitaxel 45 mg/m\\^2 IV infusion on Days 1, 8, 15 of each 3-week cycle for Cycles 2, and 3 during radiation therapy.","armGroupLabels":["Cohort A"]},{"type":"DRUG","name":"Carboplatin AUC6","description":"Carboplatin AUC6 IV infusion on Day 1 of the 21-day cycle for Cycle 1.","armGroupLabels":["Cohort A"]},{"type":"DRUG","name":"Cisplatin 75 mg/m^2","description":"Cisplatin 75 mg/m\\^2 IV infusion on Day 1 of each 21-day cycle for Cycles 1, 2, 3.","armGroupLabels":["Cohort B"]},{"type":"DRUG","name":"Pemetrexed 500 mg/m^2","description":"Pemetrexed 500 mg/m\\^2 IV infusion on Day 1 of each 21-day cycle for Cycles 1, 2, and 3.","armGroupLabels":["Cohort B"]},{"type":"RADIATION","name":"Thoracic Radiation Therapy (TRT)","description":"The target total dose of TRT will be 60 Gy in 30 daily fractions of 2 Gy, prescribed to the planning target volume.","armGroupLabels":["Cohort A","Cohort B"]},{"type":"DRUG","name":"Paclitaxel 200 mg/m^2","description":"Paclitaxel 200 mg/m\\^2 IV infusion on Day 1 of the 21-day cycle of Cycle 1.","armGroupLabels":["Cohort A"]},{"type":"DRUG","name":"Carboplatin AUC2","description":"Carboplatin AUC2 IV infusion on Day 1, 8, 15 for Cycles 2 and 3 during radiation therapy.","armGroupLabels":["Cohort A"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Percentage of Participants Who Developed Grade 3 or Higher Pneumonitis","description":"Pneumonitis included the MedDRA preferred terms for radiation pneumonitis are acute interstitial pneumonitis, autoimmune lung disease, interstitial lung disease, pneumonitis, idiopathic pneumonia syndrome, organizing pneumonia, and immune-mediated pneumonitis. As per common terminology criteria for Adverse Events, version 4.0, pneumonitis was graded as follows: Grade (Gr) 1- asymptomatic, clinical or diagnostic observations only; intervention not indicated; Gr 2- symptomatic, medical intervention indicated, limiting instrumental activities of daily living (ADL); Gr 3- severe symptoms; limiting self-care activities of daily living (ADL), oxygen indicated; Gr 4- life-threatening respiratory compromise; urgent intervention indicated (e.g., tracheotomy or intubation); Gr 5- death.","timeFrame":"Up to approximately 3 years"},{"measure":"Overall Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)","description":"ORR was defined as the percentage of participants who experienced a complete response (CR; disappearance of all target lesions) or a partial response (PR; at least a 30% decrease in the sum of diameters of target lesions) and was assessed using modified RECIST 1.1 by blinded independent central review (BICR).","timeFrame":"Up to approximately 3 years"}],"secondaryOutcomes":[{"measure":"Progression Free Survival (PFS) Per Response Criteria in Solid Tumors Version 1.1 (RECIST 1.1)","description":"PFS was defined as the time from the first dose of study treatment to the date of the first documentation of disease progression, as determined by BICR per RECIST 1.1 or death due to any cause (whichever occurred first). Disease progression was defined as at least 20 percent (%) increase (including an absolute increase of at least 5 millimeters \\[mm\\]) in the sum of diameter of target lesions, taking as reference the smallest sum, and/or unequivocal progression of existing non-target lesions, and/or appearance of 1 or more new lesions. PFS was estimated and analyzed using the product-limit (Kaplan-Meier) method for censored data.","timeFrame":"Up to approximately 5 1/2 years"},{"measure":"Overall Survival (OS)","description":"OS is defined as the time from enrollment to death due to any cause. OS was estimated and analyzed using the product-limit (Kaplan-Meier) method for censored data.","timeFrame":"Up to approximately 5 1/2 years"},{"measure":"Number of Participants Who Experienced an Adverse Event (AE)","description":"An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The number of participants with at least one AE was assessed.","timeFrame":"Up to approximately 1 1/2 years"},{"measure":"Number of Participants Who Discontinued From Study Treatment Due to an AE","description":"An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The number of participants who discontinued treatment due to an AE was assessed.","timeFrame":"Up to approximately 1 year"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Male/female participants, who are at least 18 years of age on the day of signing informed consent with previously untreated, unresectable, pathologically confirmed NSCLC and Stage IIIA, IIIB or IIIC NSCLC by American Joint Committee on Cancer Version 8.\n* No evidence of metastatic disease by whole body positron emission tomography/computed tomography (PET/ CT) scan, diagnostic quality CT scan, and brain imaging.\n* Have measurable disease per RECIST 1.1 as assessed by the local site investigator/radiology.\n* Have provided tumor tissue sample (core, incisional, or excisional biopsy).\n* Have an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1.\n* Have adequate pulmonary function test (PFT)\n* Have adequate organ function\n* A male participant must agree to use contraception through the end of treatment and refrain from donating sperm during this period.\n* A female participant is eligible to participate if she is not pregnant, not breastfeeding, and if participant is a woman of childbearing potential (WOCBP), agrees to follow the contraceptive guidance as provided in the protocol through the end of treatment.\n\nExclusion Criteria:\n\n* A WOCBP who has a positive urine pregnancy test within 72 hours prior to treatment allocation\n* Has small cell lung cancer.\n* Has had documented weight loss \\>10% in the preceding 3 months.\n* Participants whose radiation treatment plans are likely to encompass a volume of whole lung receiving \\>20 Gy in total (V20) of more than 31% of lung volume.\n* Has received prior radiotherapy to the thorax, including radiotherapy to the esophagus or for breast cancer.\n* Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent (programmed cell death protein 1 \\[PD-1\\] and its ligands, programmed cell death ligand 1 (PD-L1) and programmed cell death ligand 2 \\[PD-L2\\]) or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (eg, CTLA-4, OX-40, CD137).\n* Has received a live vaccine within 30 days prior to the first dose of study drug.\n* Has had an allogenic tissue/solid organ transplant.\n* Is currently participating in or has participated in a study of an investigational agent or has used an investigational device within 4 weeks prior to the first dose of study treatment.\n* Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg prednisone daily or equivalent) or any other form of immunosuppressive therapy within 7 days prior the first dose of study drug.\n* Has a known additional malignancy that is progressing or has required active treatment within the past 5 years.\n* Has severe hypersensitivity (Grade 3 or higher) to pembrolizumab and/or any of its excipients.\n* Has a known severe hypersensitivity (Grade 3 or higher) to any of the study chemotherapy agents and/or to any of their excipients.\n* Has an active autoimmune disease that has required systemic treatment in past 2 years (ie, with use of disease modifying agents, corticosteroids or immunosuppressive drugs).\n* Has a history of (non-infectious) pneumonitis/interstitial lung disease that required steroids or has current pneumonitis/interstitial lung disease that requires steroids.\n* Has an active infection requiring systemic therapy.\n* Has a known history of human immunodeficiency virus (HIV) infection. HIV testing is not required unless mandated by local health authority.\n* Has a known history of hepatitis B (defined as hepatitis B surface antigen \\[HBsAg\\] reactive) or known active hepatitis C virus (defined as HCV RNA \\[qualitative\\] is detected) infection.\n* Has a known history of active tuberculosis (TB; Bacillus tuberculosis).\n* Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, interfere with the participant's participation for the full duration of the study, or is not in the best interest of the participant to participate, in the opinion of the treating investigator.\n* Has a known psychiatric or substance abuse disorder that would interfere with cooperating with the requirements of the study.\n* Is pregnant or breastfeeding or expecting to conceive or father children within the projected duration of the study through the end of treatment.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Medical Director","affiliation":"Merck Sharp & Dohme LLC","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"St Joseph Heritage Healthcare ( Site 1403)","city":"Santa Rosa","state":"California","zip":"95403","country":"United States","geoPoint":{"lat":38.44047,"lon":-122.71443}},{"facility":"North Shore University Health System ( Site 1413)","city":"Evanston","state":"Illinois","zip":"60201","country":"United States","geoPoint":{"lat":42.04114,"lon":-87.69006}},{"facility":"Parkview Cancer Institute ( Site 1415)","city":"Fort Wayne","state":"Indiana","zip":"46845","country":"United States","geoPoint":{"lat":41.1306,"lon":-85.12886}},{"facility":"UMass Memorial Medical Center ( Site 1417)","city":"Worcester","state":"Massachusetts","zip":"01655","country":"United States","geoPoint":{"lat":42.26259,"lon":-71.80229}},{"facility":"Henry Ford Hospital ( Site 1418)","city":"Detroit","state":"Michigan","zip":"48202","country":"United States","geoPoint":{"lat":42.33143,"lon":-83.04575}},{"facility":"St. Francis Cancer Treatment Center ( Site 1421)","city":"Grand Island","state":"Nebraska","zip":"68803","country":"United States","geoPoint":{"lat":40.92501,"lon":-98.34201}},{"facility":"Rutgers Cancer Institute of New Jersey ( Site 1422)","city":"New Brunswick","state":"New Jersey","zip":"08903","country":"United States","geoPoint":{"lat":40.48622,"lon":-74.45182}},{"facility":"CTCA Southwestern ( Site 1428)","city":"Tulsa","state":"Oklahoma","zip":"74133","country":"United States","geoPoint":{"lat":36.15398,"lon":-95.99277}},{"facility":"Fox Chase Cancer Center ( Site 1433)","city":"Philadelphia","state":"Pennsylvania","zip":"19111","country":"United States","geoPoint":{"lat":39.95238,"lon":-75.16362}},{"facility":"Sanford Cancer Center Oncology Clinic ( Site 1434)","city":"Sioux Falls","state":"South Dakota","zip":"57104","country":"United States","geoPoint":{"lat":43.54369,"lon":-96.72796}},{"facility":"Blacktown Hospital Western Sydney Local Health District ( Site 0204)","city":"Blacktown","state":"New South Wales","zip":"2148","country":"Australia","geoPoint":{"lat":-33.76667,"lon":150.91667}},{"facility":"MNCCI Port Macquarie Base Hospital ( Site 0200)","city":"Port Macquarie","state":"New South Wales","zip":"2444","country":"Australia","geoPoint":{"lat":-31.43084,"lon":152.90894}},{"facility":"Southern Medical Day Care Centre ( Site 0201)","city":"Wollongong","state":"New South Wales","zip":"2500","country":"Australia","geoPoint":{"lat":-34.424,"lon":150.89345}},{"facility":"Ballarat Health Services ( Site 0206)","city":"Ballarat","state":"Victoria","zip":"3350","country":"Australia","geoPoint":{"lat":-37.56622,"lon":143.84957}},{"facility":"C.H. de Saint Quentin ( Site 0306)","city":"Saint-Quentin","state":"Aisne","zip":"02321","country":"France","geoPoint":{"lat":49.84889,"lon":3.28757}},{"facility":"Clinique Clairval ( Site 0311)","city":"Marseille","state":"Bouches-du-Rhone","zip":"13009","country":"France","geoPoint":{"lat":43.29695,"lon":5.38107}},{"facility":"CHU Jean Minjoz ( Site 0301)","city":"Besançon","state":"Doubs","zip":"25000","country":"France","geoPoint":{"lat":47.24878,"lon":6.01815}},{"facility":"Institut du Cancer de Montpellier ( Site 0300)","city":"Montpellier","state":"Herault","zip":"34298","country":"France","geoPoint":{"lat":43.61093,"lon":3.87635}},{"facility":"C.H.R.U. de Rennes. Hopital de Pontchaillou ( Site 0302)","city":"Rennes","state":"Ille-et-Vilaine","zip":"35033","country":"France","geoPoint":{"lat":48.11109,"lon":-1.67431}},{"facility":"ICO Centre Paul Papin ( Site 0309)","city":"Angers","state":"Maine-et-Loire","zip":"49055","country":"France","geoPoint":{"lat":47.47156,"lon":-0.55202}},{"facility":"Centre Jean Perrin ( Site 0304)","city":"Clermont-Ferrand","state":"Puy-de-Dome","zip":"63011","country":"France","geoPoint":{"lat":45.77969,"lon":3.08682}},{"facility":"Clinique de L'Europe ( Site 0308)","city":"Amiens","state":"Somme","zip":"80000","country":"France","geoPoint":{"lat":49.9,"lon":2.3}},{"facility":"Institut de Cancerologie Gustave Roussy ( Site 0305)","city":"Villejuif","state":"Val-de-Marne","zip":"94800","country":"France","geoPoint":{"lat":48.7939,"lon":2.35992}},{"facility":"Thoraxklinik Heidelberg gGmbH am Universitaetsklinikum Heidelberg ( Site 0404)","city":"Heidelberg","state":"Baden-Wurttemberg","zip":"69126","country":"Germany","geoPoint":{"lat":49.40768,"lon":8.69079}},{"facility":"Universitatsklinikum Mannheim GmbH ( Site 0413)","city":"Mannheim","state":"Baden-Wurttemberg","zip":"68167","country":"Germany","geoPoint":{"lat":49.4891,"lon":8.46694}},{"facility":"Augusta-Kranken-Anstalt Bochum ( Site 0401)","city":"Bochum","state":"North Rhine-Westphalia","zip":"44791","country":"Germany","geoPoint":{"lat":51.48165,"lon":7.21648}},{"facility":"Bethanien Krankenhaus Moers ( Site 0406)","city":"Moers","state":"North Rhine-Westphalia","zip":"47441","country":"Germany","geoPoint":{"lat":51.45342,"lon":6.6326}},{"facility":"Klinikum Chemnitz gGmbH ( Site 0410)","city":"Chemnitz","state":"Saxony","zip":"09113","country":"Germany","geoPoint":{"lat":50.8357,"lon":12.92922}},{"facility":"LungenClinic Grosshansdorf GmbH ( Site 0408)","city":"Großhansdorf","state":"Schleswig-Holstein","zip":"22927","country":"Germany","geoPoint":{"lat":53.66528,"lon":10.28552}},{"facility":"Charite Universitaetsmedizin Berlin - Campus-Virchow-Klinikum ( Site 0414)","city":"Berlin","zip":"13353","country":"Germany","geoPoint":{"lat":52.52437,"lon":13.41053}},{"facility":"Katholisches Marienkrankenhaus gGmbH ( Site 0411)","city":"Hamburg","zip":"22087","country":"Germany","geoPoint":{"lat":53.55073,"lon":9.99302}},{"facility":"Auckland City Hospital ( Site 0700)","city":"Auckland","zip":"1023","country":"New Zealand","geoPoint":{"lat":-36.84853,"lon":174.76349}},{"facility":"Centrum Onkologii im. Prof. Franciszka Lukaszczyka ( Site 0811)","city":"Bydgoszcz","state":"Kuyavian-Pomeranian Voivodeship","zip":"85-796","country":"Poland","geoPoint":{"lat":53.1235,"lon":18.00762}},{"facility":"Osrodek Badan Klinicznych przy Szpitalu Specjalistycznym ( Site 0802)","city":"Krakow","state":"Lesser Poland Voivodeship","zip":"31-826","country":"Poland","geoPoint":{"lat":50.06143,"lon":19.93658}},{"facility":"Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie ( Site 0800)","city":"Warsaw","state":"Masovian Voivodeship","zip":"02-781","country":"Poland","geoPoint":{"lat":52.22977,"lon":21.01178}},{"facility":"Szpital Morski im. PCK. Szpitale Pomorskie Sp. Z o.o ( Site 0812)","city":"Gdynia","state":"Pomeranian Voivodeship","zip":"81-519","country":"Poland","geoPoint":{"lat":54.51889,"lon":18.53188}},{"facility":"Szpital Wojewodzki w Koszalinie im. Mikolaja Kopernika ( Site 0813)","city":"Koszalin","state":"West Pomeranian Voivodeship","zip":"75-581","country":"Poland","geoPoint":{"lat":54.19438,"lon":16.17222}},{"facility":"Republican Clinical Oncology Dispensary of Republic of Bashkortostan ( Site 0903)","city":"Ufa","state":"Baskortostan, Respublika","zip":"450054","country":"Russia","geoPoint":{"lat":54.74306,"lon":55.96779}},{"facility":"Blokhin National Medical Oncology ( Site 0902)","city":"Moscow","state":"Moscow","zip":"115478","country":"Russia","geoPoint":{"lat":55.75204,"lon":37.61781}},{"facility":"National Medical Research Center of Oncology N.A. N.N. Petrov ( Site 0904)","city":"Saint Petersburg","state":"Sankt-Peterburg","zip":"197758","country":"Russia","geoPoint":{"lat":59.93863,"lon":30.31413}},{"facility":"Republican Clinical Oncology Dispensary of Tatarstan MoH ( Site 0910)","city":"Kazan'","state":"Tatarstan, Respublika","zip":"420029","country":"Russia","geoPoint":{"lat":55.78874,"lon":49.12214}},{"facility":"Chungbuk National University Hospital ( Site 1003)","city":"Cheongju-si","state":"Chungcheongbuk-do [Chungbuk]","zip":"28644","country":"South Korea","geoPoint":{"lat":36.63722,"lon":127.48972}},{"facility":"National Cancer Center ( Site 1002)","city":"Goyang-si","state":"Kyonggi-do","zip":"10408","country":"South Korea","geoPoint":{"lat":37.65639,"lon":126.835}},{"facility":"Samsung Medical Center ( Site 1001)","city":"Seoul","state":"Seoul-teukbyeolsi [Seoul]","zip":"06351","country":"South Korea","geoPoint":{"lat":37.566,"lon":126.9784}},{"facility":"Ulsan University Hospital ( Site 1000)","city":"Ulsan","state":"Ulsan-Kwangyokshi","zip":"44033","country":"South Korea","geoPoint":{"lat":35.53722,"lon":129.31667}},{"facility":"Hospital Universitari Vall d Hebron ( Site 1101)","city":"Barcelona","state":"Barcelona [Barcelona]","zip":"08035","country":"Spain","geoPoint":{"lat":41.38879,"lon":2.15899}},{"facility":"Hospital Clinic de Barcelona ( Site 1100)","city":"Barcelona","state":"Barcelona [Barcelona]","zip":"08036","country":"Spain","geoPoint":{"lat":41.38879,"lon":2.15899}},{"facility":"Hospital Son Llatzer ( Site 1105)","city":"Palma de Mallorca","state":"Illes Balears [Islas Baleares]","zip":"07198","country":"Spain","geoPoint":{"lat":39.56939,"lon":2.65024}},{"facility":"Clinica Universitaria de Navarra ( Site 1102)","city":"Madrid","zip":"28027","country":"Spain","geoPoint":{"lat":40.4165,"lon":-3.70256}},{"facility":"Hospital Universitario Virgen Macarena ( Site 1103)","city":"Seville","zip":"41009","country":"Spain","geoPoint":{"lat":37.38283,"lon":-5.97317}},{"facility":"Southampton General Hospital ( Site 1204)","city":"Southampton","state":"Hampshire","zip":"SO16 6YD","country":"United Kingdom","geoPoint":{"lat":50.90395,"lon":-1.40428}},{"facility":"Royal Free NHS Foundation Trust ( Site 1200)","city":"London","state":"London, City of","zip":"NW3 2QG","country":"United Kingdom","geoPoint":{"lat":51.50853,"lon":-0.12574}},{"facility":"Charing Cross Hospital ( Site 1208)","city":"London","state":"London, City of","zip":"W6 8RF","country":"United Kingdom","geoPoint":{"lat":51.50853,"lon":-0.12574}},{"facility":"Beacon Centre ( Site 1203)","city":"Taunton","state":"Somerset","zip":"TA1 5DA","country":"United Kingdom","geoPoint":{"lat":51.01494,"lon":-3.10293}},{"facility":"Queen's Hospital ( Site 1201)","city":"Rom Valley","state":"United Kingdom","zip":"RM7 0AG","country":"United Kingdom"},{"facility":"Leeds Teaching Hospitals NHS Trust ( Site 1209)","city":"Leeds","zip":"LS9 7TF","country":"United Kingdom","geoPoint":{"lat":53.79648,"lon":-1.54785}}]},"referencesModule":{"references":[{"pmid":"34086039","type":"RESULT","citation":"Jabbour SK, Lee KH, Frost N, Breder V, Kowalski DM, Pollock T, Levchenko E, Reguart N, Martinez-Marti A, Houghton B, Paoli JB, Safina S, Park K, Komiya T, Sanford A, Boolell V, Liu H, Samkari A, Keller SM, Reck M. Pembrolizumab Plus Concurrent Chemoradiation Therapy in Patients With Unresectable, Locally Advanced, Stage III Non-Small Cell Lung Cancer: The Phase 2 KEYNOTE-799 Nonrandomized Trial. JAMA Oncol. 2021 Jun 4;7(9):1-9. doi: 10.1001/jamaoncol.2021.2301. Online ahead of print."}],"seeAlsoLinks":[{"label":"Merck Clinical Trials Information","url":"https://www.merckclinicaltrials.com"}]},"ipdSharingStatementModule":{"ipdSharing":"YES","description":"https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf","url":"https://externaldatasharing-msd.com/"}},"resultsSection":{"participantFlowModule":{"preAssignmentDetails":"Of 216 participants enrolled/allocated in the trial, 214 received treatment.","recruitmentDetails":"Participants with unresectable, locally advanced, Stage III non-small cell lung cancer (NSCLC), who had received no prior anticancer therapy for their disease were recruited into two cohorts.","groups":[{"id":"FG000","title":"Pembrolizumab + cCRT + Paclitaxel + Carboplatin","description":"Participants received 1 cycle of carboplatin area under the curve (AUC) 6 mg/mL/min with paclitaxel 200 mg/m\\^2 and pembrolizumab 200 mg on Day 1. Approximately 3 weeks later, participants received carboplatin AUC 2 mg/mL/min with paclitaxel 45 mg/ m\\^2 administered weekly for 6 weeks along with 2 cycles of pembrolizumab 200 mg administered every 3 weeks (Q3W) in conjunction with standard thoracic radiotherapy (TRT) (60 Gray \\[Gy\\] in 2 Gy fractions administered 5 days per week for 6 weeks). Participants then received 14 additional cycles of pembrolizumab 200 mg administered Q3W. 1 cycle=21 days."},{"id":"FG001","title":"Pembrolizumab + cCRT + Pemetrexed + Cisplatin","description":"Participants received 3 cycles of cisplatin 75 mg/m\\^2 with pemetrexed 500 mg/m\\^2 and pembrolizumab 200 mg on Day 1 of each cycle. Treatment was given in conjunction with standard TRT (60 Gy in 2 Gy fractions administered 5 days per week for 6 weeks) in cycles 2 and 3. Participants then received 14 additional cycles of pembrolizumab 200 mg administered Q3W. 1 cycle=21 days."}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"112"},{"groupId":"FG001","numSubjects":"104"}]},{"type":"Treated","achievements":[{"groupId":"FG000","numSubjects":"112"},{"groupId":"FG001","numSubjects":"102"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"112"},{"groupId":"FG001","numSubjects":"104"}]}],"dropWithdraws":[{"type":"Participants Ongoing","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"}]},{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"3"}]},{"type":"Sponsor's Decision","reasons":[{"groupId":"FG000","numSubjects":"36"},{"groupId":"FG001","numSubjects":"52"}]},{"type":"Lost to Follow-up","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"}]},{"type":"Death","reasons":[{"groupId":"FG000","numSubjects":"71"},{"groupId":"FG001","numSubjects":"49"}]}]}]},"baselineCharacteristicsModule":{"populationDescription":"The analysis population consisted of all allocated participants.","groups":[{"id":"BG000","title":"Pembrolizumab + cCRT + Paclitaxel + Carboplatin","description":"Participants received 1 cycle of carboplatin area under the curve (AUC) 6 mg/mL/min with paclitaxel 200 mg/m\\^2 and pembrolizumab 200 mg on Day 1. Approximately 3 weeks later, participants received carboplatin AUC 2 mg/mL/min with paclitaxel 45 mg/ m\\^2 administered weekly for 6 weeks along with 2 cycles of pembrolizumab 200 mg administered every 3 weeks (Q3W) in conjunction with standard thoracic radiotherapy (TRT) (60 Gray \\[Gy\\] in 2 Gy fractions administered 5 days per week for 6 weeks). Participants then received 14 additional cycles of pembrolizumab 200 mg administered Q3W. 1 cycle=21 days."},{"id":"BG001","title":"Pembrolizumab + cCRT + Pemetrexed + Cisplatin","description":"Participants received 3 cycles of cisplatin 75 mg/m\\^2 with pemetrexed 500 mg/m\\^2 and pembrolizumab 200 mg on Day 1 of each cycle. Treatment was given in conjunction with standard TRT (60 Gy in 2 Gy fractions administered 5 days per week for 6 weeks) in cycles 2 and 3. Participants then received 14 additional cycles of pembrolizumab 200 mg administered Q3W. 1 cycle=21 days."},{"id":"BG002","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"112"},{"groupId":"BG001","value":"104"},{"groupId":"BG002","value":"216"}]}],"measures":[{"title":"Age, Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"Years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"65.7","spread":"9.1"},{"groupId":"BG001","value":"63.2","spread":"9.4"},{"groupId":"BG002","value":"64.5","spread":"9.3"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"36"},{"groupId":"BG001","value":"40"},{"groupId":"BG002","value":"76"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"76"},{"groupId":"BG001","value":"64"},{"groupId":"BG002","value":"140"}]}]}]},{"title":"Ethnicity (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Hispanic or Latino","measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"5"}]},{"title":"Not Hispanic or Latino","measurements":[{"groupId":"BG000","value":"101"},{"groupId":"BG001","value":"84"},{"groupId":"BG002","value":"185"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"9"},{"groupId":"BG001","value":"17"},{"groupId":"BG002","value":"26"}]}]}]},{"title":"Race (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"American Indian or Alaska Native","measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"1"}]},{"title":"Asian","measurements":[{"groupId":"BG000","value":"14"},{"groupId":"BG001","value":"11"},{"groupId":"BG002","value":"25"}]},{"title":"Native Hawaiian or Other Pacific Islander","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]},{"title":"Black or African American","measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"4"},{"groupId":"BG002","value":"5"}]},{"title":"White","measurements":[{"groupId":"BG000","value":"89"},{"groupId":"BG001","value":"75"},{"groupId":"BG002","value":"164"}]},{"title":"More than one race","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"7"},{"groupId":"BG001","value":"14"},{"groupId":"BG002","value":"21"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants Who Developed Grade 3 or Higher Pneumonitis","description":"Pneumonitis included the MedDRA preferred terms for radiation pneumonitis are acute interstitial pneumonitis, autoimmune lung disease, interstitial lung disease, pneumonitis, idiopathic pneumonia syndrome, organizing pneumonia, and immune-mediated pneumonitis. As per common terminology criteria for Adverse Events, version 4.0, pneumonitis was graded as follows: Grade (Gr) 1- asymptomatic, clinical or diagnostic observations only; intervention not indicated; Gr 2- symptomatic, medical intervention indicated, limiting instrumental activities of daily living (ADL); Gr 3- severe symptoms; limiting self-care activities of daily living (ADL), oxygen indicated; Gr 4- life-threatening respiratory compromise; urgent intervention indicated (e.g., tracheotomy or intubation); Gr 5- death.","populationDescription":"The analysis population consisted of all participants who received at least one dose of study drug.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"90% Confidence Interval","unitOfMeasure":"Percentage of Participants","timeFrame":"Up to approximately 3 years","groups":[{"id":"OG000","title":"Pembrolizumab + cCRT + Paclitaxel + Carboplatin","description":"Participants received 1 cycle of carboplatin area under the curve (AUC) 6 mg/mL/min with paclitaxel 200 mg/m\\^2 and pembrolizumab 200 mg on Day 1. Approximately 3 weeks later, participants received carboplatin AUC 2 mg/mL/min with paclitaxel 45 mg/ m\\^2 administered weekly for 6 weeks along with 2 cycles of pembrolizumab 200 mg administered every 3 weeks (Q3W) in conjunction with standard thoracic radiotherapy (TRT) (60 Gray \\[Gy\\] in 2 Gy fractions administered 5 days per week for 6 weeks). Participants then received 14 additional cycles of pembrolizumab 200 mg administered Q3W. 1 cycle=21 days."},{"id":"OG001","title":"Pembrolizumab + cCRT + Pemetrexed + Cisplatin","description":"Participants received 3 cycles of cisplatin 75 mg/m\\^2 with pemetrexed 500 mg/m\\^2 and pembrolizumab 200 mg on Day 1 of each cycle. Treatment was given in conjunction with standard TRT (60 Gy in 2 Gy fractions administered 5 days per week for 6 weeks) in cycles 2 and 3. Participants then received 14 additional cycles of pembrolizumab 200 mg administered Q3W. 1 cycle=21 days."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"112"},{"groupId":"OG001","value":"102"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.0","lowerLimit":"4.3","upperLimit":"13.6"},{"groupId":"OG001","value":"6.9","lowerLimit":"3.3","upperLimit":"12.5"}]}]}]},{"type":"PRIMARY","title":"Overall Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)","description":"ORR was defined as the percentage of participants who experienced a complete response (CR; disappearance of all target lesions) or a partial response (PR; at least a 30% decrease in the sum of diameters of target lesions) and was assessed using modified RECIST 1.1 by blinded independent central review (BICR).","populationDescription":"The analysis population consisted of all participants who received at least 1 dose of study treatment.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of Participants","timeFrame":"Up to approximately 3 years","groups":[{"id":"OG000","title":"Pembrolizumab + cCRT + Paclitaxel + Carboplatin","description":"Participants received 1 cycle of carboplatin area under the curve (AUC) 6 mg/mL/min with paclitaxel 200 mg/m\\^2 and pembrolizumab 200 mg on Day 1. Approximately 3 weeks later, participants received carboplatin AUC 2 mg/mL/min with paclitaxel 45 mg/ m\\^2 administered weekly for 6 weeks along with 2 cycles of pembrolizumab 200 mg administered every 3 weeks (Q3W) in conjunction with standard thoracic radiotherapy (TRT) (60 Gray \\[Gy\\] in 2 Gy fractions administered 5 days per week for 6 weeks). Participants then received 14 additional cycles of pembrolizumab 200 mg administered Q3W. 1 cycle=21 days."},{"id":"OG001","title":"Pembrolizumab + cCRT + Pemetrexed + Cisplatin","description":"Participants received 3 cycles of cisplatin 75 mg/m\\^2 with pemetrexed 500 mg/m\\^2 and pembrolizumab 200 mg on Day 1 of each cycle. Treatment was given in conjunction with standard TRT (60 Gy in 2 Gy fractions administered 5 days per week for 6 weeks) in cycles 2 and 3. Participants then received 14 additional cycles of pembrolizumab 200 mg administered Q3W. 1 cycle=21 days."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"112"},{"groupId":"OG001","value":"102"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"71.4","lowerLimit":"62.1","upperLimit":"79.6"},{"groupId":"OG001","value":"75.5","lowerLimit":"66.0","upperLimit":"83.5"}]}]}]},{"type":"SECONDARY","title":"Progression Free Survival (PFS) Per Response Criteria in Solid Tumors Version 1.1 (RECIST 1.1)","description":"PFS was defined as the time from the first dose of study treatment to the date of the first documentation of disease progression, as determined by BICR per RECIST 1.1 or death due to any cause (whichever occurred first). Disease progression was defined as at least 20 percent (%) increase (including an absolute increase of at least 5 millimeters \\[mm\\]) in the sum of diameter of target lesions, taking as reference the smallest sum, and/or unequivocal progression of existing non-target lesions, and/or appearance of 1 or more new lesions. PFS was estimated and analyzed using the product-limit (Kaplan-Meier) method for censored data.","populationDescription":"The analysis population consisted of all participants who received at least 1 dose of study treatment.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Months","timeFrame":"Up to approximately 5 1/2 years","groups":[{"id":"OG000","title":"Pembrolizumab + cCRT + Paclitaxel + Carboplatin","description":"Participants received 1 cycle of carboplatin area under the curve (AUC) 6 mg/mL/min with paclitaxel 200 mg/m\\^2 and pembrolizumab 200 mg on Day 1. Approximately 3 weeks later, participants received carboplatin AUC 2 mg/mL/min with paclitaxel 45 mg/ m\\^2 administered weekly for 6 weeks along with 2 cycles of pembrolizumab 200 mg administered every 3 weeks (Q3W) in conjunction with standard thoracic radiotherapy (TRT) (60 Gray \\[Gy\\] in 2 Gy fractions administered 5 days per week for 6 weeks). Participants then received 14 additional cycles of pembrolizumab 200 mg administered Q3W. 1 cycle=21 days."},{"id":"OG001","title":"Pembrolizumab + cCRT + Pemetrexed + Cisplatin","description":"Participants received 3 cycles of cisplatin 75 mg/m\\^2 with pemetrexed 500 mg/m\\^2 and pembrolizumab 200 mg on Day 1 of each cycle. Treatment was given in conjunction with standard TRT (60 Gy in 2 Gy fractions administered 5 days per week for 6 weeks) in cycles 2 and 3. Participants then received 14 additional cycles of pembrolizumab 200 mg administered Q3W. 1 cycle=21 days."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"112"},{"groupId":"OG001","value":"102"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"29.0","lowerLimit":"16.6","upperLimit":"48.5"},{"groupId":"OG001","value":"45.3","lowerLimit":"17.9","upperLimit":"NA","comment":"NA = Upper limit not reached at time of data cut-off due to insufficient number of participants with an event."}]}]}]},{"type":"SECONDARY","title":"Overall Survival (OS)","description":"OS is defined as the time from enrollment to death due to any cause. OS was estimated and analyzed using the product-limit (Kaplan-Meier) method for censored data.","populationDescription":"The analysis population consisted of all participants who received at least 1 dose of study treatment.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Months","timeFrame":"Up to approximately 5 1/2 years","groups":[{"id":"OG000","title":"Pembrolizumab + cCRT + Paclitaxel + Carboplatin","description":"Participants received 1 cycle of carboplatin area under the curve (AUC) 6 mg/mL/min with paclitaxel 200 mg/m\\^2 and pembrolizumab 200 mg on Day 1. Approximately 3 weeks later, participants received carboplatin AUC 2 mg/mL/min with paclitaxel 45 mg/ m\\^2 administered weekly for 6 weeks along with 2 cycles of pembrolizumab 200 mg administered every 3 weeks (Q3W) in conjunction with standard thoracic radiotherapy (TRT) (60 Gray \\[Gy\\] in 2 Gy fractions administered 5 days per week for 6 weeks). Participants then received 14 additional cycles of pembrolizumab 200 mg administered Q3W. 1 cycle=21 days."},{"id":"OG001","title":"Pembrolizumab + cCRT + Pemetrexed + Cisplatin","description":"Participants received 3 cycles of cisplatin 75 mg/m\\^2 with pemetrexed 500 mg/m\\^2 and pembrolizumab 200 mg on Day 1 of each cycle. Treatment was given in conjunction with standard TRT (60 Gy in 2 Gy fractions administered 5 days per week for 6 weeks) in cycles 2 and 3. Participants then received 14 additional cycles of pembrolizumab 200 mg administered Q3W. 1 cycle=21 days."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"112"},{"groupId":"OG001","value":"102"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"35.6","lowerLimit":"26.1","upperLimit":"44.2"},{"groupId":"OG001","value":"56.7","lowerLimit":"41.1","upperLimit":"NA","comment":"NA= Upper limit not reached at time of data cut-off due to insufficient number of participants with an event."}]}]}]},{"type":"SECONDARY","title":"Number of Participants Who Experienced an Adverse Event (AE)","description":"An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The number of participants with at least one AE was assessed.","populationDescription":"The analysis population consisted of all participants who received at least one dose of study drug.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Up to approximately 1 1/2 years","groups":[{"id":"OG000","title":"Pembrolizumab + cCRT + Paclitaxel + Carboplatin","description":"Participants received 1 cycle of carboplatin area under the curve (AUC) 6 mg/mL/min with paclitaxel 200 mg/m\\^2 and pembrolizumab 200 mg on Day 1. Approximately 3 weeks later, participants received carboplatin AUC 2 mg/mL/min with paclitaxel 45 mg/ m\\^2 administered weekly for 6 weeks along with 2 cycles of pembrolizumab 200 mg administered every 3 weeks (Q3W) in conjunction with standard thoracic radiotherapy (TRT) (60 Gray \\[Gy\\] in 2 Gy fractions administered 5 days per week for 6 weeks). Participants then received 14 additional cycles of pembrolizumab 200 mg administered Q3W. 1 cycle=21 days."},{"id":"OG001","title":"Pembrolizumab + cCRT + Pemetrexed + Cisplatin","description":"Participants received 3 cycles of cisplatin 75 mg/m\\^2 with pemetrexed 500 mg/m\\^2 and pembrolizumab 200 mg on Day 1 of each cycle. Treatment was given in conjunction with standard TRT (60 Gy in 2 Gy fractions administered 5 days per week for 6 weeks) in cycles 2 and 3. Participants then received 14 additional cycles of pembrolizumab 200 mg administered Q3W. 1 cycle=21 days."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"112"},{"groupId":"OG001","value":"102"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"108"},{"groupId":"OG001","value":"101"}]}]}]},{"type":"SECONDARY","title":"Number of Participants Who Discontinued From Study Treatment Due to an AE","description":"An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The number of participants who discontinued treatment due to an AE was assessed.","populationDescription":"The analysis population consisted of all participants who received at least one dose of study drug.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Up to approximately 1 year","groups":[{"id":"OG000","title":"Pembrolizumab + cCRT + Paclitaxel + Carboplatin","description":"Participants received 1 cycle of carboplatin area under the curve (AUC) 6 mg/mL/min with paclitaxel 200 mg/m\\^2 and pembrolizumab 200 mg on Day 1. Approximately 3 weeks later, participants received carboplatin AUC 2 mg/mL/min with paclitaxel 45 mg/ m\\^2 administered weekly for 6 weeks along with 2 cycles of pembrolizumab 200 mg administered every 3 weeks (Q3W) in conjunction with standard thoracic radiotherapy (TRT) (60 Gray \\[Gy\\] in 2 Gy fractions administered 5 days per week for 6 weeks). Participants then received 14 additional cycles of pembrolizumab 200 mg administered Q3W. 1 cycle=21 days."},{"id":"OG001","title":"Pembrolizumab + cCRT + Pemetrexed + Cisplatin","description":"Participants received 3 cycles of cisplatin 75 mg/m\\^2 with pemetrexed 500 mg/m\\^2 and pembrolizumab 200 mg on Day 1 of each cycle. Treatment was given in conjunction with standard TRT (60 Gy in 2 Gy fractions administered 5 days per week for 6 weeks) in cycles 2 and 3. Participants then received 14 additional cycles of pembrolizumab 200 mg administered Q3W. 1 cycle=21 days."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"112"},{"groupId":"OG001","value":"102"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"48"},{"groupId":"OG001","value":"26"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"5","timeFrame":"For adverse events: Up to ~ 1 1/2 years. All-cause mortality (ACM): Up to ~ 5 1/2 years","description":"All-cause mortality includes all enrolled participants. AEs include participants who received ≥1 dose of study treatment. Per protocol, disease progression was not considered an AE, unless related to study treatment. Thus, MedDRA preferred terms \"Neoplasm progression\", \"Malignant neoplasm progression\" and \"Disease progression\" not related to study treatment were excluded as AEs.","eventGroups":[{"id":"EG000","title":"Pembrolizumab + cCRT + Paclitaxel + Carboplatin","description":"Participants received 1 cycle of carboplatin area under the curve (AUC) 6 mg/mL/min with paclitaxel 200 mg/m\\^2 and pembrolizumab 200 mg on Day 1. Approximately 3 weeks later, participants received carboplatin AUC 2 mg/mL/min with paclitaxel 45 mg/ m\\^2 administered weekly for 6 weeks along with 2 cycles of pembrolizumab 200 mg administered every 3 weeks (Q3W) in conjunction with standard thoracic radiotherapy (TRT) (60 Gray \\[Gy\\] in 2 Gy fractions administered 5 days per week for 6 weeks). Participants then received 14 additional cycles of pembrolizumab 200 mg administered Q3W. 1 cycle=21 days.","deathsNumAffected":72,"deathsNumAtRisk":112,"seriousNumAffected":66,"seriousNumAtRisk":112,"otherNumAffected":106,"otherNumAtRisk":112},{"id":"EG001","title":"Pembrolizumab + cCRT + Pemetrexed + Cisplatin","description":"Participants received 3 cycles of cisplatin 75 mg/m\\^2 with pemetrexed 500 mg/m\\^2 and pembrolizumab 200 mg on Day 1 of each cycle. Treatment was given in conjunction with standard TRT (60 Gy in 2 Gy fractions administered 5 days per week for 6 weeks) in cycles 2 and 3. Participants then received 14 additional cycles of pembrolizumab 200 mg administered Q3W. 1 cycle=21 days.","deathsNumAffected":49,"deathsNumAtRisk":104,"seriousNumAffected":46,"seriousNumAtRisk":102,"otherNumAffected":100,"otherNumAtRisk":102}],"seriousEvents":[{"term":"Anaemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":112},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":102}]},{"term":"Autoimmune haemolytic anaemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":112},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":102}]},{"term":"Febrile neutropenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":112},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":102}]},{"term":"Haematotoxicity","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":112},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":102}]},{"term":"Neutropenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":112},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":102}]},{"term":"Pancytopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":112},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":102}]},{"term":"Thrombocytopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":112},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":102}]},{"term":"Acute myocardial infarction","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":112},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":102}]},{"term":"Atrial fibrillation","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":112},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":102}]},{"term":"Cardiac failure","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":112},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":102}]},{"term":"Cardiac failure acute","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":112},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":102}]},{"term":"Myocardial ischaemia","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":112},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":102}]},{"term":"Myocarditis","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":112},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":102}]},{"term":"Pericardial effusion","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":112},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":102}]},{"term":"Supraventricular tachycardia","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":112},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":102}]},{"term":"Tracheo-oesophageal fistula","organSystem":"Congenital, familial and genetic disorders","sourceVocabulary":"MedDRA 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":112},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":102}]},{"term":"Hyperthyroidism","organSystem":"Endocrine disorders","sourceVocabulary":"MedDRA 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":112},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":102}]},{"term":"Hypophysitis","organSystem":"Endocrine disorders","sourceVocabulary":"MedDRA 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":112},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":102}]},{"term":"Hypothyroidism","organSystem":"Endocrine disorders","sourceVocabulary":"MedDRA 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":112},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":102}]},{"term":"Abdominal pain","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":112},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":102}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":112},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":102}]},{"term":"Dysphagia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":112},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":102}]},{"term":"Gastric ulcer","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":112},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":102}]},{"term":"Gastritis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":112},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":102}]},{"term":"Gastrointestinal haemorrhage","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":112},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":102}]},{"term":"Impaired gastric emptying","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":112},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":102}]},{"term":"Intestinal obstruction","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":112},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":102}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":112},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":102}]},{"term":"Odynophagia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":112},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":102}]},{"term":"Oesophageal perforation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":112},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":102}]},{"term":"Oesophagitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":112},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":102}]},{"term":"Stomatitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":112},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":102}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":112},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":102}]},{"term":"Asthenia","organSystem":"General disorders","sourceVocabulary":"MedDRA 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":112},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":102}]},{"term":"Death","organSystem":"General disorders","sourceVocabulary":"MedDRA 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":112},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":102}]},{"term":"Device related thrombosis","organSystem":"General disorders","sourceVocabulary":"MedDRA 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":112},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":102}]},{"term":"Fatigue","organSystem":"General disorders","sourceVocabulary":"MedDRA 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":112},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":102}]},{"term":"Pyrexia","organSystem":"General disorders","sourceVocabulary":"MedDRA 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":112},{"groupId":"EG001","numEvents":9,"numAffected":7,"numAtRisk":102}]},{"term":"Sudden death","organSystem":"General disorders","sourceVocabulary":"MedDRA 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":112},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":102}]},{"term":"Cholecystitis acute","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":112},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":102}]},{"term":"Drug-induced liver injury","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":112},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":102}]},{"term":"Hepatitis acute","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":112},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":102}]},{"term":"Hepatobiliary disease","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":112},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":102}]},{"term":"Anaphylactic reaction","organSystem":"Immune system disorders","sourceVocabulary":"MedDRA 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":112},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":102}]},{"term":"Drug hypersensitivity","organSystem":"Immune system disorders","sourceVocabulary":"MedDRA 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":112},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":102}]},{"term":"Anal abscess","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":112},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":102}]},{"term":"Biliary tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":112},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":102}]},{"term":"Bronchitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":112},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":102}]},{"term":"Bronchitis bacterial","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":112},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":102}]},{"term":"COVID-19","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":112},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":102}]},{"term":"COVID-19 pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":112},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":102}]},{"term":"Catheter site infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":112},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":102}]},{"term":"Cellulitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":112},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":102}]},{"term":"Cystitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":112},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":102}]},{"term":"Device related infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":112},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":102}]},{"term":"Encephalitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":112},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":102}]},{"term":"Infectious pleural effusion","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":112},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":102}]},{"term":"Infective exacerbation of chronic obstructive airways disease","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":112},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":102}]},{"term":"Lower respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":112},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":102}]},{"term":"Neutropenic sepsis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":2,"numAtRisk":112},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":102}]},{"term":"Orchitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":112},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":102}]},{"term":"Pneumocystis jirovecii pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":112},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":102}]},{"term":"Pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":15,"numAffected":14,"numAtRisk":112},{"groupId":"EG001","numEvents":11,"numAffected":9,"numAtRisk":102}]},{"term":"Pneumonia necrotising","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":112},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":102}]},{"term":"Pneumonia pneumococcal","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":112},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":102}]},{"term":"Pyelonephritis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":112},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":102}]},{"term":"Respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":112},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":102}]},{"term":"Sepsis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":4,"numAtRisk":112},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":102}]},{"term":"Urinary tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":112},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":102}]},{"term":"Radiation oesophagitis","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":112},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":102}]},{"term":"Radiation pneumonitis","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":112},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":102}]},{"term":"Spinal compression fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":112},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":102}]},{"term":"Tibia fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":112},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":102}]},{"term":"Neutrophil count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":112},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":102}]},{"term":"Platelet count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":112},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":102}]},{"term":"Dehydration","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":112},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":102}]},{"term":"Electrolyte imbalance","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":112},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":102}]},{"term":"Failure to thrive","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":112},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":102}]},{"term":"Hyperglycaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":112},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":102}]},{"term":"Hypophagia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":112},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":102}]},{"term":"Type 2 diabetes mellitus","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":112},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":102}]},{"term":"Hypertrophic osteoarthropathy","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":112},{"groupId":"EG001","numEvents":2,"numAffected":1,"numAtRisk":102}]},{"term":"Non-Hodgkin's lymphoma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":112},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":102}]},{"term":"Dizziness","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":112},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":102}]},{"term":"Hypertensive encephalopathy","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":112},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":102}]},{"term":"Ischaemic stroke","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":112},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":102}]},{"term":"Metabolic encephalopathy","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":112},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":102}]},{"term":"Syncope","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":112},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":102}]},{"term":"Transient ischaemic attack","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":112},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":102}]},{"term":"Acute kidney injury","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":112},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":102}]},{"term":"Chronic kidney disease","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":112},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":102}]},{"term":"Prerenal failure","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":112},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":102}]},{"term":"Atelectasis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":112},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":102}]},{"term":"Chronic obstructive pulmonary disease","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":112},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":102}]},{"term":"Interstitial lung disease","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":112},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":102}]},{"term":"Pleural effusion","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":112},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":102}]},{"term":"Pneumonitis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":7,"numAffected":7,"numAtRisk":112},{"groupId":"EG001","numEvents":5,"numAffected":5,"numAtRisk":102}]},{"term":"Pneumothorax","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":112},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":102}]},{"term":"Pulmonary embolism","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":112},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":102}]},{"term":"Pulmonary haemorrhage","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":112},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":102}]},{"term":"Respiratory failure","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":112},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":102}]},{"term":"Rash maculo-papular","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":112},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":102}]},{"term":"Toxic epidermal necrolysis","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":112},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":102}]},{"term":"Arterial occlusive disease","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":112},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":102}]},{"term":"Deep vein thrombosis","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":112},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":102}]},{"term":"Embolism","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":112},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":102}]},{"term":"Thrombophlebitis","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":112},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":102}]}],"otherEvents":[{"term":"Anaemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":53,"numAffected":44,"numAtRisk":112},{"groupId":"EG001","numEvents":40,"numAffected":33,"numAtRisk":102}]},{"term":"Leukopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":29,"numAffected":15,"numAtRisk":112},{"groupId":"EG001","numEvents":11,"numAffected":8,"numAtRisk":102}]},{"term":"Lymphopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":13,"numAffected":11,"numAtRisk":112},{"groupId":"EG001","numEvents":16,"numAffected":12,"numAtRisk":102}]},{"term":"Neutropenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":50,"numAffected":32,"numAtRisk":112},{"groupId":"EG001","numEvents":29,"numAffected":23,"numAtRisk":102}]},{"term":"Thrombocytopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":22,"numAffected":17,"numAtRisk":112},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":102}]},{"term":"Tachycardia","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":9,"numAffected":8,"numAtRisk":112},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":102}]},{"term":"Tinnitus","organSystem":"Ear and labyrinth disorders","sourceVocabulary":"MedDRA 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":112},{"groupId":"EG001","numEvents":13,"numAffected":11,"numAtRisk":102}]},{"term":"Vertigo","organSystem":"Ear and labyrinth disorders","sourceVocabulary":"MedDRA 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":6,"numAtRisk":112},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":102}]},{"term":"Hyperthyroidism","organSystem":"Endocrine disorders","sourceVocabulary":"MedDRA 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":9,"numAffected":9,"numAtRisk":112},{"groupId":"EG001","numEvents":9,"numAffected":8,"numAtRisk":102}]},{"term":"Hypothyroidism","organSystem":"Endocrine disorders","sourceVocabulary":"MedDRA 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":19,"numAffected":18,"numAtRisk":112},{"groupId":"EG001","numEvents":16,"numAffected":15,"numAtRisk":102}]},{"term":"Abdominal pain","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":8,"numAffected":8,"numAtRisk":112},{"groupId":"EG001","numEvents":7,"numAffected":6,"numAtRisk":102}]},{"term":"Abdominal pain upper","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":3,"numAtRisk":112},{"groupId":"EG001","numEvents":7,"numAffected":7,"numAtRisk":102}]},{"term":"Constipation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":28,"numAffected":24,"numAtRisk":112},{"groupId":"EG001","numEvents":32,"numAffected":27,"numAtRisk":102}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":37,"numAffected":27,"numAtRisk":112},{"groupId":"EG001","numEvents":27,"numAffected":22,"numAtRisk":102}]},{"term":"Dyspepsia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":17,"numAffected":15,"numAtRisk":112},{"groupId":"EG001","numEvents":9,"numAffected":7,"numAtRisk":102}]},{"term":"Dysphagia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":31,"numAffected":27,"numAtRisk":112},{"groupId":"EG001","numEvents":16,"numAffected":16,"numAtRisk":102}]},{"term":"Gastrooesophageal reflux disease","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":112},{"groupId":"EG001","numEvents":6,"numAffected":6,"numAtRisk":102}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":36,"numAffected":28,"numAtRisk":112},{"groupId":"EG001","numEvents":77,"numAffected":53,"numAtRisk":102}]},{"term":"Odynophagia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":14,"numAffected":11,"numAtRisk":112},{"groupId":"EG001","numEvents":5,"numAffected":5,"numAtRisk":102}]},{"term":"Oesophagitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":20,"numAffected":17,"numAtRisk":112},{"groupId":"EG001","numEvents":25,"numAffected":24,"numAtRisk":102}]},{"term":"Stomatitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":8,"numAffected":7,"numAtRisk":112},{"groupId":"EG001","numEvents":7,"numAffected":6,"numAtRisk":102}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":11,"numAffected":10,"numAtRisk":112},{"groupId":"EG001","numEvents":23,"numAffected":20,"numAtRisk":102}]},{"term":"Asthenia","organSystem":"General disorders","sourceVocabulary":"MedDRA 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":26,"numAffected":20,"numAtRisk":112},{"groupId":"EG001","numEvents":60,"numAffected":41,"numAtRisk":102}]},{"term":"Chest pain","organSystem":"General disorders","sourceVocabulary":"MedDRA 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":7,"numAffected":7,"numAtRisk":112},{"groupId":"EG001","numEvents":12,"numAffected":10,"numAtRisk":102}]},{"term":"Chills","organSystem":"General disorders","sourceVocabulary":"MedDRA 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":6,"numAtRisk":112},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":102}]},{"term":"Fatigue","organSystem":"General disorders","sourceVocabulary":"MedDRA 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":49,"numAffected":39,"numAtRisk":112},{"groupId":"EG001","numEvents":38,"numAffected":33,"numAtRisk":102}]},{"term":"Mucosal inflammation","organSystem":"General disorders","sourceVocabulary":"MedDRA 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":6,"numAtRisk":112},{"groupId":"EG001","numEvents":10,"numAffected":10,"numAtRisk":102}]},{"term":"Pyrexia","organSystem":"General disorders","sourceVocabulary":"MedDRA 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":30,"numAffected":22,"numAtRisk":112},{"groupId":"EG001","numEvents":14,"numAffected":13,"numAtRisk":102}]},{"term":"Pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":14,"numAffected":12,"numAtRisk":112},{"groupId":"EG001","numEvents":5,"numAffected":5,"numAtRisk":102}]},{"term":"Upper respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":9,"numAffected":8,"numAtRisk":112},{"groupId":"EG001","numEvents":5,"numAffected":5,"numAtRisk":102}]},{"term":"Urinary tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":8,"numAffected":7,"numAtRisk":112},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":102}]},{"term":"Radiation oesophagitis","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":13,"numAffected":13,"numAtRisk":112},{"groupId":"EG001","numEvents":15,"numAffected":14,"numAtRisk":102}]},{"term":"Radiation pneumonitis","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":18,"numAffected":18,"numAtRisk":112},{"groupId":"EG001","numEvents":12,"numAffected":12,"numAtRisk":102}]},{"term":"Radiation skin injury","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":112},{"groupId":"EG001","numEvents":8,"numAffected":8,"numAtRisk":102}]},{"term":"Alanine aminotransferase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":9,"numAffected":8,"numAtRisk":112},{"groupId":"EG001","numEvents":9,"numAffected":8,"numAtRisk":102}]},{"term":"Aspartate aminotransferase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":8,"numAffected":8,"numAtRisk":112},{"groupId":"EG001","numEvents":6,"numAffected":4,"numAtRisk":102}]},{"term":"Blood creatinine increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":7,"numAffected":6,"numAtRisk":112},{"groupId":"EG001","numEvents":17,"numAffected":13,"numAtRisk":102}]},{"term":"Blood urea increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":112},{"groupId":"EG001","numEvents":9,"numAffected":7,"numAtRisk":102}]},{"term":"Lymphocyte count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":16,"numAffected":11,"numAtRisk":112},{"groupId":"EG001","numEvents":12,"numAffected":8,"numAtRisk":102}]},{"term":"Neutrophil count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":23,"numAffected":19,"numAtRisk":112},{"groupId":"EG001","numEvents":15,"numAffected":13,"numAtRisk":102}]},{"term":"Platelet count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":18,"numAffected":16,"numAtRisk":112},{"groupId":"EG001","numEvents":15,"numAffected":9,"numAtRisk":102}]},{"term":"Weight decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":16,"numAffected":16,"numAtRisk":112},{"groupId":"EG001","numEvents":14,"numAffected":14,"numAtRisk":102}]},{"term":"White blood cell count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":17,"numAffected":11,"numAtRisk":112},{"groupId":"EG001","numEvents":19,"numAffected":11,"numAtRisk":102}]},{"term":"Decreased appetite","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":29,"numAffected":24,"numAtRisk":112},{"groupId":"EG001","numEvents":34,"numAffected":30,"numAtRisk":102}]},{"term":"Dehydration","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":5,"numAtRisk":112},{"groupId":"EG001","numEvents":7,"numAffected":6,"numAtRisk":102}]},{"term":"Hyperglycaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":13,"numAffected":9,"numAtRisk":112},{"groupId":"EG001","numEvents":11,"numAffected":6,"numAtRisk":102}]},{"term":"Hypoalbuminaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":8,"numAffected":6,"numAtRisk":112},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":102}]},{"term":"Hypokalaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":10,"numAffected":9,"numAtRisk":112},{"groupId":"EG001","numEvents":8,"numAffected":6,"numAtRisk":102}]},{"term":"Hyponatraemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":15,"numAffected":10,"numAtRisk":112},{"groupId":"EG001","numEvents":5,"numAffected":3,"numAtRisk":102}]},{"term":"Arthralgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":22,"numAffected":17,"numAtRisk":112},{"groupId":"EG001","numEvents":13,"numAffected":11,"numAtRisk":102}]},{"term":"Back pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":8,"numAffected":6,"numAtRisk":112},{"groupId":"EG001","numEvents":7,"numAffected":5,"numAtRisk":102}]},{"term":"Musculoskeletal chest pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":8,"numAffected":6,"numAtRisk":112},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":102}]},{"term":"Myalgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":14,"numAffected":11,"numAtRisk":112},{"groupId":"EG001","numEvents":9,"numAffected":8,"numAtRisk":102}]},{"term":"Dizziness","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":11,"numAffected":9,"numAtRisk":112},{"groupId":"EG001","numEvents":11,"numAffected":9,"numAtRisk":102}]},{"term":"Dysgeusia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":11,"numAffected":10,"numAtRisk":112},{"groupId":"EG001","numEvents":8,"numAffected":8,"numAtRisk":102}]},{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":9,"numAffected":9,"numAtRisk":112},{"groupId":"EG001","numEvents":18,"numAffected":13,"numAtRisk":102}]},{"term":"Neuropathy peripheral","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":15,"numAffected":15,"numAtRisk":112},{"groupId":"EG001","numEvents":5,"numAffected":5,"numAtRisk":102}]},{"term":"Paraesthesia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":7,"numAffected":6,"numAtRisk":112},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":102}]},{"term":"Peripheral sensory neuropathy","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":13,"numAffected":12,"numAtRisk":112},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":102}]},{"term":"Insomnia","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":21,"numAffected":18,"numAtRisk":112},{"groupId":"EG001","numEvents":8,"numAffected":7,"numAtRisk":102}]},{"term":"Cough","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":36,"numAffected":31,"numAtRisk":112},{"groupId":"EG001","numEvents":37,"numAffected":29,"numAtRisk":102}]},{"term":"Dyspnoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":28,"numAffected":24,"numAtRisk":112},{"groupId":"EG001","numEvents":19,"numAffected":18,"numAtRisk":102}]},{"term":"Oropharyngeal pain","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":112},{"groupId":"EG001","numEvents":8,"numAffected":8,"numAtRisk":102}]},{"term":"Pleural effusion","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":8,"numAffected":8,"numAtRisk":112},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":102}]},{"term":"Pneumonitis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":19,"numAffected":16,"numAtRisk":112},{"groupId":"EG001","numEvents":19,"numAffected":17,"numAtRisk":102}]},{"term":"Productive cough","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":8,"numAffected":8,"numAtRisk":112},{"groupId":"EG001","numEvents":9,"numAffected":9,"numAtRisk":102}]},{"term":"Alopecia","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":35,"numAffected":35,"numAtRisk":112},{"groupId":"EG001","numEvents":6,"numAffected":6,"numAtRisk":102}]},{"term":"Pruritus","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":19,"numAffected":15,"numAtRisk":112},{"groupId":"EG001","numEvents":18,"numAffected":16,"numAtRisk":102}]},{"term":"Rash","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":27,"numAffected":22,"numAtRisk":112},{"groupId":"EG001","numEvents":16,"numAffected":14,"numAtRisk":102}]},{"term":"Rash maculo-papular","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":6,"numAtRisk":112},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":102}]},{"term":"Hypertension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":6,"numAtRisk":112},{"groupId":"EG001","numEvents":7,"numAffected":5,"numAtRisk":102}]},{"term":"Hypotension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":11,"numAffected":11,"numAtRisk":112},{"groupId":"EG001","numEvents":7,"numAffected":6,"numAtRisk":102}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"OTHER","restrictiveAgreement":true,"otherDetails":"If publication activity is not directed by the Sponsor, the investigator agrees to submit all manuscripts or abstracts to the Sponsor before submission. This allows the Sponsor to protect proprietary information and to provide comments."},"pointOfContact":{"title":"Senior Vice President, Global Clinical Development","organization":"Merck Sharp & Dohme LLC","email":"ClinicalTrialsDisclosure@msd.com","phone":"1-800-672-6372"}}},"documentSection":{"largeDocumentModule":{"largeDocs":[{"typeAbbrev":"Prot_SAP","hasProtocol":true,"hasSap":true,"hasIcf":false,"label":"Study Protocol and Statistical Analysis Plan","date":"2022-12-05","uploadDate":"2025-03-06T14:15","filename":"Prot_SAP_001.pdf","size":1534205}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2025-12-17"},"conditionBrowseModule":{"meshes":[{"id":"D002289","term":"Carcinoma, Non-Small-Cell Lung"},{"id":"C565324","term":"Parkinson Disease 4, Autosomal Dominant Lewy Body"}],"ancestors":[{"id":"D002283","term":"Carcinoma, Bronchogenic"},{"id":"D001984","term":"Bronchial Neoplasms"},{"id":"D008175","term":"Lung Neoplasms"},{"id":"D012142","term":"Respiratory Tract Neoplasms"},{"id":"D013899","term":"Thoracic Neoplasms"},{"id":"D009371","term":"Neoplasms by Site"},{"id":"D009369","term":"Neoplasms"},{"id":"D008171","term":"Lung Diseases"},{"id":"D012140","term":"Respiratory Tract Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"C582435","term":"pembrolizumab"},{"id":"D017239","term":"Paclitaxel"},{"id":"D002945","term":"Cisplatin"},{"id":"D000068437","term":"Pemetrexed"}],"ancestors":[{"id":"D043823","term":"Taxoids"},{"id":"D043822","term":"Cyclodecanes"},{"id":"D003516","term":"Cycloparaffins"},{"id":"D006840","term":"Hydrocarbons, Alicyclic"},{"id":"D006844","term":"Hydrocarbons, Cyclic"},{"id":"D006838","term":"Hydrocarbons"},{"id":"D009930","term":"Organic Chemicals"},{"id":"D004224","term":"Diterpenes"},{"id":"D013729","term":"Terpenes"},{"id":"D017606","term":"Chlorine Compounds"},{"id":"D007287","term":"Inorganic Chemicals"},{"id":"D017672","term":"Nitrogen Compounds"},{"id":"D017671","term":"Platinum Compounds"},{"id":"D006147","term":"Guanine"},{"id":"D007042","term":"Hypoxanthines"},{"id":"D011688","term":"Purinones"},{"id":"D011687","term":"Purines"},{"id":"D006574","term":"Heterocyclic Compounds, 2-Ring"},{"id":"D000072471","term":"Heterocyclic Compounds, Fused-Ring"},{"id":"D006571","term":"Heterocyclic Compounds"},{"id":"D005971","term":"Glutamates"},{"id":"D024342","term":"Amino Acids, Acidic"},{"id":"D000596","term":"Amino Acids"},{"id":"D000602","term":"Amino Acids, Peptides, and Proteins"},{"id":"D000600","term":"Amino Acids, Dicarboxylic"}]}},"hasResults":true}